**Core tip:** Male breast cancer (BC) is typically diagnosed at an advanced stage, most likely due to a lack of awareness that men can develop BC. Therefore, in case of a large tumor, a flap-based thoracic reconstruction may be required.

INTRODUCTION
============

Breast cancer (BC) in men represents between 0.5% and 1% of all breast cancers diagnosed each year\[[@B1]\]. Few epidemiological or clinical trial data on male BC are available. The disease appears to share similar risk factors and characteristics with postmenopausal BC in women\[[@B2]\]. Favorable parameters, such as low nuclear grade and positive hormone receptor status, are more common for men and postmenopausal women than for premenopausal women. As in women, the most common subtype is invasive ductal carcinoma, while lobular tumor types are rarely diagnosed in men. In contrast to female BC, men are significantly more likely to present with a more advanced stage at diagnosis and with lymph node involvement\[[@B3]\]. We report an interesting case of a large papillary invasive breast cancer in a 62-year-old man.

CASE REPORT
===========

A 62-year-old Caucasian male presented at the certified Breast Cancer Center, Klinikum Pinneberg, Germany, with a newly diagnosed large, symptomatic mass in the left breast. Clinical examination showed a not movable mass of 16 cm diameter, deforming the whole breast (Figure [1](#F1){ref-type="fig"}); the overlying skin was livid and hypervascularized. Enlarged lymph nodes were palpable in the axillary pit. He had no concomitant diseases at time of presentation; his previous surgeries included circumcision as a child and he was a nonsmoker. He denied any first- or second degree family medical history of cancer of any type and he never received radiotherapy. His serum estradiol levels were normal. The patient reported that he had noticed the tumor one year prior to presentation; the reason for eventually seeing a doctor was an increasing pain, most likely due to the pressure on the skin by the growing tumor. There was no nipple discharge. At ultrasound, the lesion was scored BI-RADS 5 (Figure [2](#F2){ref-type="fig"}). Axillary lymph nodes were suspicious on sonography. Mammography was not possible due to tenderness on palpation.

![Photodocumentation at time of presentation.](WJCO-7-420-g001){#F1}

![Breast ultrasound shows a large irregular structure of low echogenicity with spiculae measuring \> 15 cm × 15 cm (BI-RADS 5).](WJCO-7-420-g002){#F2}

Ultrasound guided minimal-invasive 14-gauge core biopsy revealed a moderately differentiated non-invasive encapsulated papillary carcinoma with high expression of estrogen and progesterone receptors (both \> 80%, IRS 12) and HER2-negative (Figure [3](#F3){ref-type="fig"}). Because of the tumor size a mastectomy with axillary dissection and chest wall reconstruction using a latissimus dorsi (LADO) flap was performed. Histological analysis showed invasive growth besides typical non-invasive papillary carcinoma and was classified as invasive solid papillary carcinoma (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). The TNM stage was pT3 (10 cm), pN0 (0/15), M0 and the resection margins were at least 5 mm in all directions. After discussion in our interdisciplinary tumor board we conducted the OncotypeDX test which indicated low risk (Recurrence Score: 2). Radiation therapy and tamoxifen were recommended. The patient was referred for genetic counseling but decided against genetic testing. He had an uneventful recovery and is disease-free after two years of follow-up (Figure [6](#F6){ref-type="fig"}).

![Solid papillary carcinoma (*in situ*), composed of expansile rounded nodular epithelial masses. A: Low magnification 12.5 ×; B: Low magnification 25 ×.](WJCO-7-420-g003){#F3}

![Relatively bland tumor cells with ovoid nuclei and indistinct nucleoli. Fine fibrovascular septa are seen within the epithelial islands (medium magnification, 100 ×).](WJCO-7-420-g004){#F4}

![Solid papillary carcinoma (invasive) - tumor cell islands with irregular jagged contours within a desmoplastic stroma (medium magnification, 50 ×).](WJCO-7-420-g005){#F5}

![Postoperative clinical presentation.](WJCO-7-420-g006){#F6}

DISCUSSION
==========

To our knowledge, this is the first case report on a giant invasive papillary carcinoma in a man treated by LADO flap-based reconstruction of the thoracic wall. Papillary breast cancer is a very rare type of BC with an estimated incidence of approximately 1% of all breast cancer cases\[[@B4]\]. In terms of histopathology, papillary carcinoma refers to a morphologically heterogeneous group of lesions, all of which are characterized by arborescent fibrovascular stalks lined by epithelial cells. In most cases of invasive papillary carcinoma, ductal carcinoma *in situ* is also present. Available epidemiological data suggest an improved survival of patients with papillary carcinoma in comparison to the more common invasive ductal cancer\[[@B4]\]. In men, papillary tumor type is more common than in women: In a large series of 778 men with invasive BC, 34 (4.4%) were diagnosed with this tumor subtype\[[@B5]\]. In case of our patient, the minimally invasive core biopsy showed in situ papillary cancer, while the examination of the whole surgical specimen revealed invasive growth as well.

According to the epidemiological data from the Surveillance, Epidemiology, and End Results Program of the American National Cancer Institute, men tend to be older than women at the time of diagnosis, with a median age of 67 years compared with 62 years for women\[[@B3]\]. Further, men are more likely to be diagnosed with advanced disease: At time of diagnosis, 20% of women had tumors smaller than 1 cm compared with only 9.8% of men, 38% of men had regional lymph node involvement compared with 29% of women, and more men had distant metastasis at time of diagnosis than women. On the other hand, tumor biology appeared to be more favourable in men than in women: Men have a significantly higher proportion of hormone receptor positive tumors than women (91% of men and 76% of women present with ER-positive disease)\[[@B3]\]. With regard to molecular gene expression assays, there is limited evidence available related specifically to men, although tumors in men display very similar gene signatures to those in women\[[@B6]\] and OncotypeDX-based clinical trials such as the Ontario trial include male BC patients as well\[[@B7]\]. With respect to risk factors, genetic factors including BRCA mutations, family history, age, androgen/estrogen imbalance, radiation therapy and environmental exposures seem to predispose to male breast cancer\[[@B8]\]. In context of genetic counseling, BRCA2 germline mutation leads to a 100-fold increase in breast cancer risk in male carriers while this association is less established for the BRCA1 mutation. The cumulative risk of BC for male BRCA1 mutation carriers at age 70 years is 1.2% compared to 6.8% for BRCA2 mutation carriers\[[@B9]\]. Another risk factor, the excessive estrogen stimulation, may be due to exogenous hormonal exposure (*i.e*., hormonal treatment or estrogen-containing compounds/testosterone), overweight, chronic liver diseases and thyroid disease\[[@B10]\]. Men with Klinefelter syndrome are more at risk for developing breast cancer as well\[[@B11]\].

The approach to men with a suspicious breast mass is similar to that of women and includes mammography, ultrasound and biopsy (Table [1](#T1){ref-type="table"}). As in women, male breast cancer is classified according to the TNM staging system and tumor biology (estrogen receptor, progesterone receptor and HER2 status) is crucial for choosing adequate systemic therapy. Most men with early stage disease undergo a simple mastectomy. Flap-based reconstruction of the thoracic wall may be necessary in case of a very large tumor\[[@B12]\]. Both the LADO flap and the abdominal tissue transfer, such as transverse rectus abdominis muscle flap or deep inferior epigastric perforator flap, are reliable techniques. The use of LADO flap in a variety of reconstructive settings has been described since early 20^th^ century\[[@B13]\]. In this surgical technique, the pedicled musculocutaneous flap is dissected along with the fat and skin overlying the vascularized muscle and tunneled subcutaneously under the axilla to be transposed into the wound in the thoracic wall. Beyond breast or thoracic wall reconstruction, the LADO flap may be used in men for phalloplasty after penile trauma or in case of congenital anomalies of the penis; in this setting, the flap is not pedicled but is transferred as a "free flap" to another body site and the circulation is re-established *via* microsurgical anastomosis between the flap and the femoral vessels\[[@B14]\].

###### 

The comparison of male and female breast cancer with respect to diagnostics and therapy

                                   **Female breast cancer**                                                                                                       **Male breast cancer**
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------
  Epidemiology                     Very common (125 new cases per 100000 women per year)                                                                          Very rare (1.2 new cases per 100000 men per year)
  Average age at diagnosis         62 yr                                                                                                                          67 yr
  Diagnostics                      Mammography, sonography; in selected cases MRI                                                                                 Sonography; mammography if possible; in selected cases MRI
  Association with BRCA mutation   5%-10% of all cases are BRCA-positive                                                                                          10%-20% of all cases are BRCA-positive
  Surgery                          Breast-conserving surgery (70%-80% patients) or mastectomy; sentinel node biopsy in cN0                                        Mastectomy; sentinel node biopsy in cN0
  Reconstruction techniques        Implant or flap-based reconstruction after mastectomy                                                                          Flap-based reconstruction of thoracic wall in case of a large tumor
  Chemotherapy                     Recommendation depends on tumor biology and tumor load; adjuvant or neoadjuvant use; usually anthracycline- and taxane-based   
  Endocrine therapy                Recommended in hormone receptor positive tumors; tamoxifen or aromatase inhibitor                                              Recommended in hormone receptor positive tumors; tamoxifen
  HER2-targeted treatment          Trastuzumab recommended in HER2-positive tumors                                                                                
  Radiation therapy                                                                                                                                               Thoracic wall or lymph node radiation in case of higher tumor load
                                   Recommended after breast-conserving surgery; thoracic wall or lymph node radiation in case of higher tumor load                

MRI: Magnetic resonance imaging; HER2: Human epidermal growth factor receptor 2.

Most experts agree that sentinel node biopsy should be performed in early male breast cancer in absence of clinically or sonographically suspicious nodes; this approach is in accordance with the ASCO clinical guidelines\[[@B15]\]. Although large clinical trials on sentinel node biopsy in men have not been carried out, smaller studies confirm this technique to be as feasible as in women\[[@B16],[@B17]\].

As in women, adjuvant therapy of male breast cancer may include radiation therapy, endocrine therapy, chemotherapy, and HER2-targeted treatment. In the absence of large clinical trials focusing on male BC, therapy recommendations radiation therapy, chemo- and HER2-therapy mirror those for women. In the context of endocrine therapy, the use of tamoxifen rather than an aromatase inhibitor is recommended\[[@B18]\].

COMMENTS
========

Case characteristics
--------------------

A 62-year-old male with a newly diagnosed large, symptomatic mass in the left breast.

Clinical diagnosis
------------------

A not movable mass of 16 cm diameter, deforming the whole breast; the overlying skin livid and hypervascularized; enlarged lymph nodes in the axillary pit.

Differential diagnosis
----------------------

Benign breast tumor.

Imaging diagnosis
-----------------

Ultrasound: Large irregular structure of low echogenicity with spiculae (BI-RADS 5), suspicious axillary lymph nodes.

Pathological diagnosis
----------------------

Core biopsy: Moderately differentiated non-invasive encapsulated papillary carcinoma with high expression of estrogen and progesterone receptors (both \> 80%, IRS 12) and HER2-negative. Surgical specimen: Invasive solid papillary carcinoma, pT3, pN0 (0/15), M0, OncotypeDX low risk (Recurrence Score: 2).

Treatment
---------

Mastectomy with axillary dissection and chest wall reconstruction using a latissimus dorsi flap.

Experiences and lessons
-----------------------

This case report describes a rare case of male papillary breast cancer and emphasizes the importance of flap-based reconstruction in case of a large tumor.

Peer-review
-----------

This is a case report of rare men breast cancer and then the author gave a short literature review. The review provides some useful information.
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